Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII.

Molecular genetics and metabolism | 2012

Mucopolysaccharidosis type VII (MPS VII) is characterized by deficient β-glucuronidase (GUSB) activity, which leads to accumulation of chondroitin, heparan and dermatan sulfate glycosaminoglycans (GAGs), and multisystemic disease. MPS VII patients can develop kypho-scoliotic deformity and spinal cord compression due to disease of intervertebral disks, vertebral bodies, and associated tissues. We have previously demonstrated in MPS VII dogs that intervertebral disks degenerate, vertebral bodies have irregular surfaces, and vertebral body epiphyses have reduced calcification, but the pathophysiological mechanisms underlying these changes are unclear. We hypothesized that some of these manifestations could be due to upregulation of destructive proteases, possibly via the binding of GAGs to Toll-like receptor 4 (TLR4), as has been proposed for other tissues in MPS models. In this study, the annulus fibrosus of the intervertebral disk of 6-month-old MPS VII dogs had cathepsin B and K activities that were 117- and 2-fold normal, respectively, which were associated with elevations in mRNA levels for these cathepsins as well as TLR4. The epiphyses of MPS VII dogs had a marked elevation in mRNA for the cartilage-associated gene collagen II, consistent with a developmental delay in the conversion of the cartilage to bone in this region. The spine obtained at autopsy from a young man with MPS VII exhibited similar increased cartilage in the vertebral bodies adjacent to the end plates, disorganization of the intervertebral disks, and irregular vertebral end plate morphology. These data suggest that the pathogenesis of destructive changes in the spine in MPS VII may involve upregulation of cathepsins. Inhibition of destructive proteases, such as cathepsins, might reduce spine disease in patients with MPS VII or related disorders.

Pubmed ID: 22513347 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCRR NIH HHS, United States
    Id: P40 RR002512
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK054481
  • Agency: NICHD NIH HHS, United States
    Id: R01 HD061879-02
  • Agency: NIH HHS, United States
    Id: OD012095
  • Agency: NCRR NIH HHS, United States
    Id: P40 RR002512-27
  • Agency: NICHD NIH HHS, United States
    Id: HD061879
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK054481-17
  • Agency: NICHD NIH HHS, United States
    Id: R01 HD061879
  • Agency: NCRR NIH HHS, United States
    Id: RR002512
  • Agency: NIDDK NIH HHS, United States
    Id: DK054481

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Phoenix Pharmaceuticals (tool)

RRID:SCR_001141

Commercial antibody supplier that specializes in peptide-related products for research in obesity, cardiovascular disease, and diabetes.

View all literature mentions